2024年1月2日 · HCQ is recommended for all patients with lupus at a target dose 5 mg/kg real body weight/day, considering the individual's risk for flares and retinal toxicity. GC are used as 'bridging therapy' during periods of disease activity; for maintenance treatment, they should be minimised to equal or less than 5 mg/day (prednisone equivalent) and ...

Systemic lupus erythematosus (SLE) is a complex autoimmune disease with variable clinical features (1; 2). SLE manifestations are associated with multiple autoantibodies, ensuing immune complex formation and deposition, and other immune processes (2; 3).

Since 2008, when the first EULAR recommen-dations for the management of systemic lupus erythematosus (SLE) were published and widely adopted,1 a series of specific recommendations on disease monitoring, neuropsychiatric SLE and lupus nephritis (LN), pregnancy and women’s health issues in SLE have been developed.2–5 More

2023年10月13日 · The European Alliance of Associations for Rheumatology (EULAR) has updated its recommendations for the management of systemic lupus erythematosus (SLE) based on emerging new evidence. For the 2023 updated recommendations, a Task Force of world-leading experts in the field of SLE from four continents were assembled to conduct a systematic ...

Our objective was to update the EULAR recommendations for the management of systemic lupus erythematosus (SLE), based on emerging new evidence. We performed a systematic literature review (01/2007-12/2017), followed by modified Delphi method, to form questions, elicit expert opinions and reach conse …

Systemic lupus erythematosus (SLE) is a complex disease with variable presentations, course and prognosis. We sought to develop evidence-based recommendations addressing the major issues in the management of SLE. The EULAR Task Force on SLE comprised 19 specialists and a clinical epidemiologist.

2024年7月22日 · The 2023 update of the EULAR recommendations for the management of systemic lupus erythematosus (SLE) faced several tasks: the newly approved medications anifrolumab and voclosporin as well as the additional approval of belimumab for lupus nephritis had to be conceptionally fitted into the management of SLE.

Highlights include further reductions in the recommended maintenance dose of glucocorticoids (GC), a strong recommendation for early use of conventional and biologic immunosuppressive drugs and the use of combination therapies in lupus nephritis (LN).

ANA = antinuclear antibodies; anti-dsDNA = anti–double-stranded (ds) DNA; EULAR/ACR = European League Against Rheumatism/American College of Rheumatology; SLE = systemic lupus erythematosus.

Since 2008, when the first EULAR recommendations for the management of systemic lupus erythematosus (SLE) were published and widely adopted,1 a series of specific recommendations on disease monitoring, neuropsychiatric SLE and lupus nephritis (LN), pregnancy and women’s health issues in SLE have been developed.2–5 More recently, updated ...